Coastem Kemon announced on the 26th that it has submitted an application for approval of a Phase 1/2a clinical trial plan to evaluate the safety and efficacy of combined treatment with allogeneic bone marrow-derived mesenchymal stem cells and immunosuppressants in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.


Hot Picks Today

"If It's Uncomfortable, They Cut Ties": Three Out of Five U.S. Gen Z Have Broken Off Contact With Family or Friends in the Past Year "If It's Uncomfortable, They Cut Ties": Three O...

한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing